Stocks opened lower on Friday after China said it will slap new tariffs on U.S. goods.US Marketsread more
Powell repeated his pledge Friday to keep the economic expansion going while acknowledging that tariffs and other factors are causing growth to slow.The Fedread more
China says the new tariffs will begin Sept. 1 and Dec. 15. That's when President Trump's latest tariffs on Chinese goods are to take effect.Marketsread more
The idea came up as the White House brainstorms on ways to avoid a preelection economic slowdown, The Washington Post reports.US Economyread more
The Koch brothers financed one of the most influential political networks in the modern era. The sprawling political empire includes conservative and libertarian nonprofits...Politicsread more
At least three members of Facebook's Libra organization are considering leaving the operation due to intense regulatory scrutiny.Technologyread more
Google on Friday released a new set of community guidelines that are meant to crack down on what employees can say inside the company.Technologyread more
Emails between Facebook employees from 2015 illustrate early actions the company took to investigate third-party use of their data.Technologyread more
Andrew McCabe filed a lawsuit alleging that his removal was part of a scheme by President Donald Trump to remove government employees "because they were not politically loyal...Politicsread more
Falling air cargo demand could be flashing warning signs about the broader economy.Transportationread more
Moulton was one of the few candidates not to make the debate stages in June and July.2020 Electionsread more
Procter & Gamble has agreed to acquire Merck KGaA's consumer health unit for 3.4 billion euros ($4.2 billion), giving it vitamin brands such as Seven Seas and greater exposure to Latin American and Asian markets.
The maker of Pampers diapers and Gillette razors said the deal would help it expand its portfolio of consumer healthcare products which includes Vicks cold relief.
The Merck unit includes vitamin brands Femibion and Neurobion.
Prescription-free remedies offer stable sales due to customers' brand loyalty, albeit at lower margins than pharmaceuticals.
But intense price competition online, mainly from Amazon, as well as cheaper store-brand products have weighed on profits in the U.S. and other Western markets.
U.S.-based P&G derived 12 percent of group sales, or $7.5 billion, from health-care products last year, including Oral-B toothbrushes and toothpastes.
The purchase price for Merck's business suggests that the German company climbed down from price demands of as much as 4 billion euros, which sources told Reuters had deterred initial suitors such as Nestle, Perrigo, and Stada owners Bain and Cinven.
Morgan Stanley analyst Vincent Meunier said the price still implied a valuation of 4.7 times sales and around 19 times operating profit (EBITDA) for the business, at the high end of recent deals in the sector.
"This will help (Merck) focus on its pharma unit and refurbish its pipeline," he said.
Merck shares were up 0.5 percent higher, among top gainers in the German blue-chip DAX index, having risen 1.2 percent earlier.
Merck said that it fetched a multiple of about 19.5, above recent industry transactions and based on an adjusted "economically transferred" EBITDA of 173 million euros in 2017.
The proceeds would allow it to reduce debt faster, giving its businesses, which include chemicals, pharmaceuticals and lab equipment, more flexibility, although it ruled out acquisitions worth more than 500 million euros this year.
P&G also announced it will split up its consumer care joint venture with Teva, PGT Healthcare, on July 1, saying strategies were no longer aligned.
PGT accounts for nearly all of P&G's personal health care sales outside of the United States.
Teva said the terms of the agreement to terminate the JV with P&G would not be disclosed and that the dissolution was amicable.
Merck said the divestment of its consumer health business did not change its goal of keeping net sales of its established prescription drugs, such as Erbitux against cancer and multiple sclerosis treatment Rebif, organically stable until 2022.
It will issue guidance for 2018 to reflect the sale of the consumer healthcare business with it publishes first-quarter financial results on May 15, it said.
About 3,300 Merck employees could move to P&G upon completion of the transaction, which is expected by the fourth quarter.
As part of the deal, P&G will buy a majority stake in the German company's Indian consumer health business, Merck, and subsequently make a mandatory tender offer to minority shareholders.
A final agreement with P&G on Merck's French consumer health business has yet to be worked out with labor representatives but that will not change the overall price agreed with P&G.
JPMorgan acted as financial adviser to Merck on the transaction, and Freshfields Bruckhaus Deringer was legal adviser.